Chronic lymphocytic leukemia (CLL) represents the most prevalent adult leukemia and is characterized by the accumulation of long-lived B lymphocytes. Despite significant advances in its therapy ...

In the last few years, multispecific antibodies, such as bispecific, trispecific, and tetraspecific antibodies, have become the breakthrough stars in antibody therapeutics. Compared with ...

These features allow the antibodies to reach the site of action at high concentrations, and the improvements in pharmacokinetics are expected to increase patient convenience, treatment adherence ...

The dual-specificity of bispecific antibody drugs has allowed an expansion of possible mechanisms of action, which enhances the potential of this novel class of drugs as potential cancer ...

antagonize the action of TSH and cause hypothyroidism. The latter occurs most notably in the neonate as a result of a mother with antibodies due to AITD. TPO antibodies (TPOAb) appear involved in ...

Testing for these antibodies and additional biomarkers can ... The doctor will interpret the results before recommending further action.

Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company with a market capitalization of $2.8 billion, has announced the publication detailing the mechanism of action for its investigational ...

HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47. AK132 is an asymmetric bispecific ...

A new snakebite treatment combines an existing drug with antibodies from a hyperimmune reptile collector, raising both hopes and ethical concerns ...